Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005022 · ClinicalTrials.gov registry record · Phase 1
Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Small Cell Lung Cancer
A Phase 1 study, sponsored by Radiation Therapy Oncology Group.
- Completed
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
NCT00005022 is a Phase 1 study that has completed, run by Radiation Therapy Oncology Group. The registered enrollment target is 64 participants.
The verdict
NCT00005022, a Phase 1 study, has completed, sponsored by Radiation Therapy Oncology Group.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining more than one chemotherapy drug with radiation therapy may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of radiation therapy plus combination chemotherapy in treating patients with limited-stage small cell lung cancer.
Interventions
- DRUG cisplatin
- DRUG etoposide
- RADIATION radiation therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 1998-02 |
| Est. Completion | 2010-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005022
The ClinicalTrials.gov registry entry for NCT00005022 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Radiation Therapy Oncology Group, which has 144 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which cisplatin is the first listed.
NCT00005022 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00005022 about?
NCT00005022 is a clinical study titled "Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Small Cell Lung Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining more than one chemotherapy drug with radiation therapy may kill more tumor cells. PURPOSE: Phase I trial...
What is the current status of trial NCT00005022?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 1998-02. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00005022?
The interventions under investigation include: cisplatin (DRUG), etoposide (DRUG), radiation therapy (RADIATION).
Who is sponsoring clinical trial NCT00005022?
This trial is sponsored by Radiation Therapy Oncology Group, which has 144 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.